Please login to the form below

Bluebird Bio

This page shows the latest Bluebird Bio news and features for those working in and with pharma, biotech and healthcare.

Bluebird Bio’s LentiGlobin candidate is currently in phase 1/2 testing and has been able to nearly eliminate VOCs in the first treated patients.

CAR-Ts take centre stage as ASH18 comes to a close

LCAR-B38M, including an 88% overall response rate among a group of 57 patients that analysts suggest seems to hold up well against data presented by Bluebird Bio for its
Amgen’s BCMA drug on course to challenge CAR-Ts in myeloma

BiTE will rival therapies from Bluebird, Celgene/Juno, J&J/Legend biotech. Amgen has its first data on bispecific antibody AMG 420, one of a swathe of BCMA-targeting therapies with ... busy field at first glance, although it remains to be seen whether it
ASH18: CAR-T and drugs give new options for multiple myeloma

San Diego congress showcasing data in important haematology markets. Celgene and Bluebird Bio’s anti-BCMA CAR-T bb21217 is effective in patients with very advanced multiple myeloma, and crucially seems
BCMA in the spotlight as ASH abstracts drop

The publication of the ASH abstracts yesterday revels no fewer than 51 presentations involving BCMA, including a slew of CAR-T therapies from Bluebird Bio/Celgene, Juno/Celgene, Nanjing Legend/GenScript ... Bluebird/Celgene’s CAR-T bb2121 is currently
Orchard plans IPO as gene therapy pipeline advances

Orchard is playing catch-up in thalassaemia with Bluebird Bio, which is planning to file its LentiGlobin candidate in Europe before the end of this year, but getting PRIME status in

More from news
Approximately 6 fully matching, plus 22 partially matching documents found.

Regeneron and Bluebird sign $100m cell therapies deal

Six targets chosen from TCR and other cell therapy platforms. ‘Big biotech’ Regeneron and cell and gene therapy specialists Bluebird Bio have unveiled a new collaboration which gives both greater presence ... The collaboration with Regeneron
Bluebird Bio: on the cusp of a gene therapy revolution

Bluebird Bio's chief executive Nick Leschly. Cell and gene therapy made the transition from an interesting but unproven science to medical reality in 2017, with two ‘living medicine’ CAR-T ... The next company to play its hand in this biotech-led
Deal Watch September 2016

The lead programme EM801 is a T cell bispecific antibody targeting B-cell maturation antigen (BCMA), which s considered to be complementary to Bluebird bio's CAR T cell therapies targeting ... 1, 695. Medigene /Bluebird bio. Licence. Development and
Pharma deals in May 2015

Interestingly though, it is not always the major players as evidenced by the deals between bluebird bio with Five Prime Therapeutics and Editas with Juno Therapeutics. ... Five Prime/ bluebird bio. Licence agreement. For development of CAR-T cell
Deal Watch table for June 2014

208. Pregenen/ bluebird bio. Company acquisition. Gene editing technology platform. 156.

More from intelligence
Approximately 1 fully matching, plus 5 partially matching documents found.

Proteostasis Therapeutics strengthens leadership team

James DeTore (pictured) becomes the biopharmaceutical firm's chief financial officer, bringing experience from bluebird bio, Ironwood Pharmaceuticals and Microbia.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Senior Account Manager, Rare Diseases – Medical Communications, ...: Excellent package

Senior Account Director development role to Business Director, H...: Excellent package

Global Business Development Director – Health Education: excellent commission

Engagement Expert, Healthcare Brand Communications, London: Excellent package

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Client Services Director – Medical Education Agency – North West...: Salary TBC

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Add my company

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

NHS regional footprints: What to expect from 2019...
Not another weight-loss ad: Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up: As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...